Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.42 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519553 | 0.91 | PDE5A (0.49) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL9913970 | 0.89 | PDE5A (0.53) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL16264700 | 0.81 | PDE5A (0.49) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL9913945 | 0.80 | ADORA3 (0.52) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL16264773 | 0.80 | PDE5A (0.59) | PDE5AADORA3KCNH2 | |
| SCHEMBL9913972 | 0.80 | PDE5A (0.51) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL9914119 | 0.78 | ADORA3 (0.55) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL9913984 | 0.78 | PDE5A (0.48) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL9913921 | 0.78 | ADORA3 (0.54) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL9913979 | 0.75 | PDE5A (0.65) | PDE5AADORA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216978-B2 | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-22 | — | — | US | disclosed |
| US-20140350020-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| WO-2012004258-A9 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350020-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | TYMS, DHFR, DPYD | PDE5A 1379/4885ADORA3 1578/4885KCNH2 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.